Fabry Disease and the Heart: A Comprehensive Review

Fabry Disease and the Heart: A Comprehensive Review

Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations of the <i>GLA</i> gene that result in a deficiency of the enzymatic activity of α-galactosidase A and consequent accumulation of glycosphingolipids in body fluids and lysosomes of the cells throughout the bo...

Full description

Bibliographic Details
Main Authors:	Olga Azevedo, Filipa Cordeiro, Miguel Fernandes Gago, Gabriel Miltenberger-Miltenyi, Catarina Ferreira, Nuno Sousa, Damião Cunha
Format:	Article
Language:	English
Published:	MDPI AG 2021-04-01
Series:	International Journal of Molecular Sciences
Subjects:	Fabry disease heart cardiomyopathy enzyme replacement therapy migalastat
Online Access:	https://www.mdpi.com/1422-0067/22/9/4434

Similar Items

Fabry Disease Therapy: State-of-the-Art and Current Challenges
by: Olga Azevedo, et al.
Published: (2020-12-01)

Impact of enzyme replacement therapy and migalastat on left atrial strain and cardiomyopathy in patients with Fabry disease
by: Christian Pogoda, et al.
Published: (2023-11-01)

Strong increase of leukocyte apha‐galactosidase A activity in two male patients with Fabry disease following oral chaperone therapy
by: Foudil Lamari, et al.
Published: (2019-09-01)

Sphingosine-1-Phosphate Levels Are Higher in Male Patients with Non-Classic Fabry Disease
by: Wladimir Mauhin, et al.
Published: (2022-02-01)

Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?
by: Fernando Perretta, et al.
Published: (2023-02-01)

The GALA project: practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts
by: Cristina Chimenti, et al.
Published: (2020-04-01)

Long-Term Monitoring of Cardiac Involvement under Migalastat Treatment Using Magnetic Resonance Tomography in Fabry Disease
by: Constantin Gatterer, et al.
Published: (2023-05-01)

Biomarkers for Monitoring Renal Damage Due to Fabry Disease in Patients Treated with Migalastat: A Review for Nephrologists
by: Sebastián Jaurretche, et al.
Published: (2022-09-01)

Diagnosis of Fabry Disease in a Patient with a Surgically Repaired Congenital Heart Defect: When Clinical History and Genetics Make the Difference
by: Marta Rubino, et al.
Published: (2022-02-01)

Migalastat como monoterapia oral para la enfermedad de Fabry
by: Fernando Javier Perretta, et al.
Published: (2023-01-01)

A review and recommendations for oral chaperone therapy in adult patients with Fabry disease
by: Michał Nowicki, et al.
Published: (2024-01-01)

Enfermedad de Fabry: un año en tratamiento con migalastat
by: Juan Camilo Vasquez Gomez, et al.
Published: (2022-09-01)

The New Pharmacological Chaperones PBXs Increase α-Galactosidase A Activity in Fabry Disease Cellular Models
by: Pedro Besada, et al.
Published: (2021-12-01)

Kidney Transplant in Fabry Disease: A Revision of the Literature
by: Irene Capelli, et al.
Published: (2020-06-01)

Long‐Term Clinical‐Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy
by: Andrea Frustaci, et al.
Published: (2024-04-01)

Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis
by: Taciane Alegra, et al.
Published: (2012-01-01)

Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease
by: Il Young Kim, et al.
Published: (2021-12-01)

Fabry Disease: A Turkish Case with a Novel Mutation and Dermatological Manifestations
by: Neslihan Onenli Mungan, et al.
Published: (2015-03-01)

Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina
by: Gustavo Cabrera, et al.
Published: (2017-06-01)

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
by: Christoph Wanner, et al.
Published: (2020-06-01)

Fabry Cardiomyopathy: Current Practice and Future Directions
by: Jeffrey Yim, et al.
Published: (2021-06-01)

Pulmonary manifestations and the effectiveness of enzyme replacement therapy in Fabry Disease with the p. Arg227Ter (p.R227*) mutation
by: Päivi Pietilä‐Effati, et al.
Published: (2022-05-01)

Fabry Cardiomyopathy: Current Treatment and Future Options
by: Irfan Vardarli, et al.
Published: (2021-07-01)

Clinical course and management of fabry disease in three patients before the introduction of enzyme replacement therapy
by: Franc Verovnik
Published: (2006-12-01)

Case report: enzyme replacement therapy for Fabry disease presenting with proteinuria and ventricular septal thickening
by: Zewei Chen, et al.
Published: (2024-02-01)

Clinical evaluation, accurate diagnosis and treatment of four pedigrees with Fabry's disease
by: Peng Gou, et al.
Published: (2023-02-01)

Enzyme Replacement Therapy in the Treatment of Fabry Disease
by: YU Che, et al.
Published: (2023-07-01)

Fabry Nephropathy: An Evidence-Based Narrative Review
by: María del Pino, et al.
Published: (2018-03-01)

Misfolding of Lysosomal α-Galactosidase a in a Fly Model and Its Alleviation by the Pharmacological Chaperone Migalastat
by: Hila Braunstein, et al.
Published: (2020-10-01)

Anderson-Fabry’s Disease: A Rare but Treatable Case of Fever of Unknown Origin
by: Francesca Graziani, et al.
Published: (2017-09-01)

Lipid profile in adult patients with Fabry disease - Ten-year follow up
by: Karolina M. Stepien, et al.
Published: (2017-12-01)

Fabry Hastalığı: Yeni Bir Mutasyon ve Cilt Bulgulariyla Seyreden Bir Türk O
by: Neslihan MUNGAN, et al.
Published: (2015-10-01)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
by: Michael Beck, et al.
Published: (2015-06-01)

Biomarkers of Myocardial Fibrosis: Revealing the Natural History of Fibrogenesis in Fabry Disease Cardiomyopathy
by: Patrício Aguiar, et al.
Published: (2018-03-01)

A renal variant of Fabry disease: A case with a novel Gal A hemizygote mutation
by: Jorge H. Mukdsi, et al.
Published: (2012-10-01)

Clinical features and enzyme replacement therapy in 10 children with Fabry disease
by: Qian Li, et al.
Published: (2023-02-01)

Updated Evaluation of Agalsidase Alfa Enzyme Replacement Therapy for Patients with Fabry Disease: Insights from Real-World Data
by: Feriozzi S, et al.
Published: (2024-04-01)

Treatment of Fabry Nephropathy: A Literature Review
by: Homare Shimohata, et al.
Published: (2023-08-01)

Evidence of evolution towards left midventricular obstruction in severe Anderson–Fabry cardiomyopathy
by: Francesca Graziani, et al.
Published: (2021-02-01)

Ascending aortic remodelling in Fabry disease after long-term enzyme replacement therapy
by: Pierre Monney, et al.
Published: (2017-10-01)